| Full text | |
| Author(s): |
Radaic, Allan
[1]
;
Martins-de-Souza, Daniel
[1, 2, 3, 4]
Total Authors: 2
|
| Affiliation: | [1] Univ Campinas UNICAMP, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Campinas - Brazil
[2] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBION, Sao Paulo - Brazil
[3] DOr Inst Res & Educ IDOR, Sao Paulo - Brazil
[4] Univ Estadual Campinas, Expt Med Res Cluster EMRC, Campinas, SP - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | Nanomedicine-Nanotechnology Biology and Medicine; v. 28, AUG 2020. |
| Web of Science Citations: | 0 |
| Abstract | |
Schizophrenia is one of the top 25 causes of global diseases burdens in terms of years lived with the disease and the emotional and economical strains it imposes on the society. Several strategies have been used to treat the patients, specially using typical and atypical psychoactives. However, due to its multifactorial characteristic and patient resistance, schizophrenia is still a difficult disease to diagnose and treat. Thus, new strategies for diagnostics and treatment must be researched to optimize the efficacy and reduce the side effects of the actual therapy. Nanomedicine tries to improve low-weight molecular agents for treatment of diseases through the use of nanoscaled carriers. Among nanomedicine, nanopsychiatry specifically deals with the potential role of nanotechnology in solving psychiatry diseases problems. Therefore, the objective of this work is to provide an overview of the state of the art of nanopsychiatry in the sense of treating schizophrenia. (C) 2020 Elsevier Inc. All rights reserved. (AU) | |
| FAPESP's process: | 17/25588-1 - From the basic understanding to clinical biomarkers to schizophrenia: a neuroproteomics-centered multidisciplinary study |
| Grantee: | Daniel Martins-de-Souza |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 13/08711-3 - Developing a predictive test for a successful medication response and understanding the molecular bases of schizophrenia through proteomics |
| Grantee: | Daniel Martins-de-Souza |
| Support Opportunities: | Research Grants - Young Investigators Grants |
| FAPESP's process: | 18/03673-0 - Biochemical effects of cannabinoids on oligodendrocytes: implications for schizophrenia |
| Grantee: | Daniel Martins-de-Souza |
| Support Opportunities: | Regular Research Grants |